Group 1: Company Overview and Market Position - Inner Mongolia Furu Medical Technology Co., Ltd. is actively engaging with various investment firms and stakeholders to enhance its market presence [2][3]. - The company has installed a total of 215 units of FibroScan GO as of August 2023, with 70% of these installations in the United States [4][5]. - The expected compound annual growth rate (CAGR) for revenue over the next five years is projected to reach approximately 40% [5]. Group 2: Product and Technology Insights - FibroScan GO has been successfully integrated into various healthcare settings, with a focus on expanding its application beyond liver health to include gastrointestinal and primary care [4][6]. - The pricing for a single FibroScan test varies by region, with costs in the U.S. being $108 in private clinics and $130-140 in hospitals, making it economically viable and competitive [5]. - Echosens has developed a comprehensive customer process for FibroScan GO, ensuring effective installation and training for optimal usage [6]. Group 3: Strategic Partnerships and Collaborations - Echosens collaborates with over 50 pharmaceutical and biotechnology companies for NASH clinical trials, with more than 90% utilizing FibroScan for patient screening and efficacy evaluation [7]. - The company has established partnerships with major pharmaceutical firms, including Novo Nordisk and Intercept, to support drug development and market expansion in the NASH field [7][8]. Group 4: Financial Performance and Projections - Theraclion's revenue for 2022 was approximately €1.4 million, with a loss of €4.9 million, while the first half of 2023 showed a revenue increase of 183% to €0.981 million [8]. - The company aims to enhance its revenue streams through FDA certification and the development of AI-driven technologies to improve device performance [8]. Group 5: Future Directions and Goals - The company plans to provide services to 300,000 patients over the next ten years, aiming for a 15% reduction in liver cancer incidence and a 30% increase in five-year survival rates [8][9]. - Echosens is focused on expanding its market reach, particularly in the endocrine and primary care sectors, as it broadens the indications for FibroScan usage [6][9].

Environmental Commitment and Social Responsibility - The company emphasizes its commitment to environmental protection and sustainable development, continuously improving production processes and enhancing employee awareness of environmental issues[4]. - The company received the "2022 Annual Public Welfare Collective Award" and the "2022 Annual Public Welfare Project Award" for its social responsibility initiatives[5]. - The company is actively participating in social welfare projects, reflecting its dedication to community service[5]. - The company is committed to continuous improvement in its operational practices to align with legal and environmental standards[4]. - There were no significant environmental penalties reported during the reporting period, and the company complied with all relevant environmental laws[21]. - The company has not faced any major risks or penalties related to environmental issues during the reporting period[32]. Financial Performance - The company achieved operating revenue of 524 million yuan, a year-on-year increase of 16.79%[72]. - The net profit attributable to shareholders was 43.82 million yuan, up 34.63% year-on-year[72]. - The net profit after deducting non-recurring gains and losses was 46.74 million yuan, an increase of 40.99% compared to the same period last year[72]. - The company's operating revenue for the reporting period was ¥524,483,977.36, representing a 16.79% increase compared to ¥449,072,570.45 in the same period last year[86]. - The company's R&D investment increased by 17.12% to ¥57,373,250.36 from ¥48,987,756.62 year-on-year[86]. - The net cash flow from operating activities surged by 186.76% to ¥120,050,398.95, up from ¥41,864,609.74 in the previous year[91]. - The company reported a revenue of 500 million RMB for the first half of 2023, representing a 20% increase year-over-year[199]. - The company has provided a revenue guidance of 1.2 billion RMB for the full year 2023, reflecting an expected growth of 25%[199]. Employee Engagement and Incentives - In 2022, the company's performance assessment indicator completion rate was 90.71%, resulting in a total of 182.82 million shares allocated under the employee stock ownership plan, accounting for 0.70% of the total share capital[17]. - The first batch of the employee stock ownership plan in 2021 resulted in 201.55 million shares allocated, representing 0.77% of the total share capital[17]. - The company has implemented a comprehensive employee incentive mechanism, focusing on both short-term and long-term rewards to enhance employee engagement and performance[23]. - The employee stock ownership plan currently involves 92 participants, reflecting a commitment to employee engagement and retention[27]. - The employee stock ownership plan includes 92 participants holding a total of 6,718,233 shares, representing 2.55% of the company's total equity[186]. - The employee stock ownership plan is funded through employees' legal salaries and self-raised funds, with no financial assistance provided by the company[186]. Corporate Governance and Compliance - There were no bankruptcy reorganization matters during the reporting period[1]. - The company reported no non-operating fund occupation by controlling shareholders or other related parties during the reporting period[11]. - There were no violations regarding external guarantees during the reporting period[12]. - The half-year financial report has not been audited[15]. - The company has ongoing commitments from major shareholders to avoid competition and maintain share lock-up for 36 months post-IPO[8]. - The company is focused on maintaining stable control by its actual controller and has commitments in place to prevent any actions that could jeopardize this[10]. - The company has actively communicated with investors through various channels, ensuring transparency and timely information disclosure[22]. - The company reported no significant litigation or arbitration matters during the reporting period[175]. - There were no major related party transactions or asset acquisitions during the reporting period[176][177]. - The company has a good integrity status with no major debts or court judgments pending against it[175]. - The company reported a stable management team with no significant changes in senior management during the reporting period[171]. - The company has not engaged in any major mergers or acquisitions during the reporting period[176]. Research and Development - The company plans to continue focusing on NAFLD/NASH diagnosis and treatment, enhancing R&D capabilities and international collaborations[76]. - The company is focused on enhancing its liver disease diagnostic technology, aiming to develop more diverse and intelligent products[82]. - The company launched the FibroScan domestic product series, which integrates advanced technology tailored to meet the clinical needs of Chinese doctors[82]. - Research and development investment has increased by 40%, totaling 50 million RMB, to support innovation initiatives[199]. Market Strategy and Expansion - The company plans to expand its sales channels to include retail pharmacies, e-commerce platforms, and internet hospitals[73]. - The company aims to enhance its competitive edge by accelerating strategic transformation and increasing investment in the Internet + healthcare sector[146]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2024[199]. - A strategic acquisition of a local competitor is anticipated to enhance the company's product portfolio and increase market penetration by 30%[199]. - The company is exploring partnerships with healthcare providers to expand service offerings and increase revenue streams by 20%[199]. Risk Management - The company faces risks from macroeconomic changes and will actively adapt its business strategies to mitigate these risks[162]. - The company acknowledges the risk of new business developments not meeting expectations and plans to conduct thorough research on potential acquisitions[149]. - The company is aware of the increasing competition in the healthcare market and is adjusting its strategies accordingly[163]. Investment and Assets - The company holds a 50.09% stake in Echosens, with net profit for the reporting period reaching 78,806,334.00, contributing 21.03% to the company's net assets[134]. - The company invested 6,000,000.00 in Theraclion, acquiring a 28.21% stake, with the first round of capital increase completed[138]. - The total investment in the Furu Health Technology Park project reached 4,703,273.40, with a cumulative actual investment of 188,926,704.56[140]. - The fair value of trading financial assets at the end of the period was 76,787,666.51, with a purchase amount of 65,379,227.59 and a sale amount of 124,791,501.08 during the period[135]. - The company's total assets amounted to 979,853,775.44, with significant overseas assets contributing to its net asset structure[134]. - The company's long-term equity investments increased to CNY 117,149,427.40, up from CNY 60,684,293.52, marking a 2.10% increase in proportion[110]. - The company's inventory increased to CNY 120,656,839.06, representing 4.64% of total assets, up from 3.86% the previous year[110].

公司独立董事就该事项发表了同意的独立意见。具体内容详见公司在巨潮资讯网上 上发布的相关公告。 特此公告。 内蒙古福瑞医疗科技股份有限公司董事会 二零二三年八月二十九日 附件：简历 卢奕伟，男，新加坡国籍，1978 年 12 月出生，博士。2011 年至 2014 年，任罗氏制 药临床前研究、研究员；2015 年至 2019 年，任吉利德科学东南亚医学事务肝炎负责人、 大中国区肝炎医学事务负责人；2019 年至 2020 年，任歌礼生物医学事务部负责人；2020 年至 2023 年，任强生集团子公司西安杨森制药医学事务部抗感染和疫苗领域负责人；2023 年 1 月至 2023 年 4 月，任武田制药医学事务部罕见病领域负责人；2023 年 4 月至 2023 年 8 月，任华辉安健生命科技有限公司医学事务部负责人。 证券代码：300049 证券简称：福瑞股份 公告编号：2023-042 内蒙古福瑞医疗科技股份有限公司 关于聘任副总经理的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 内蒙古福瑞医疗科技股份有限公司（以下简称"公司"）于 2023 年 8 月 ...

一、审议通过了《关于<2023 年半年度报告及摘要>的议案》 证券代码：300049 证券简称：福瑞股份 公告编号：2023-039 内蒙古福瑞医疗科技股份有限公司 第八届监事会第三次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 2023 年 8 月 18 日，本公司以电子邮件方式，向全体监事发出了《关于召开第八届监 事会第三次会议的通知》及相关议案。根据《公司章程》和《监事会议事规则》的有关 规定，公司监事会于 2023 年 8 月 28 日在公司以通讯方式召开了第八届监事会第三次会 议，本次会议为定期会议，监事会主席王立群女士主持了本次会议，会议应参加表决监 事 5 人，实际参加表决监事 5 人。本次会议的召开符合《公司法》和《公司章程》的规 定。 全体出席会议的监事经过认真审议、表决，形成如下决议： 具体内容详见公司于同日刊登在巨潮资讯网上的《2023 年半年度报告》全文及摘要。 监事会认为：公司《2023 年半年度报告》的编制和审核程序符合法律、行政法规和 中国证监会的规定，报告内容真实、准确、完整地反映了公司的实际情况，不存在任何 虚 ...

证券代码：300049 证券简称：福瑞股份 公告编号：2023-040 内蒙古福瑞医疗科技股份有限公司 关于对外捐赠的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、对外捐赠事项概述 内蒙古福瑞医疗科技股份有限公司（以下简称"公司"）于 2023 年 8 月 28 日召开第八 届董事会第三次会议，审议通过了《关于对外捐赠的议案》，同意公司及子公司以自有 资金向各类慈善公益组织捐赠不超过人民币 1000 万元，款项主要用于肝病相关课题研究、 社区筛查等。为保证合法、高效地完成本次捐赠工作，公司董事会授权管理层在上述额 度范围内负责对外捐赠事项的实施。本次对外捐赠额度经公司董事会审议通过之日起 12 个月内有效。 根据《深圳证券交易所创业板股票上市规则》《公司章程》等有关规定，本次捐赠 事项在董事会决策范围内，无需提交公司股东大会审议。本次对外捐赠事项不构成关联 交易，亦不构成《上市公司重大资产重组管理办法》规定的重大资产重组。 二、捐赠目的和对公司的影响 独立董事认为：本次对外捐赠是公司积极履行社会责任、回馈社会的举措，符合公 司的经营宗旨和价值观的要 ...

证券代码：300049 证券简称：福瑞股份 公告编号：2023-038 内蒙古福瑞医疗科技股份有限公司 第八届董事会第三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2023 年 8 月 18 日，本公司以电子邮件的方式，向全体董事发出了《关于召开第八届 董事会第三次会议的通知》及相关议案。根据《公司章程》和《董事会议事规则》的有 关规定，公司董事会于 2023 年 8 月 28 日以通讯方式召开了第八届董事会第三次会议， 本次会议为定期会议，董事长王冠一先生主持了本次会议。会议应参加表决董事 7 人， 实际参加表决董事 7 人。公司监事、高级管理人员列席了本次会议。本次会议的召开符 合《公司法》和《公司章程》的规定。 公司独立董事对该事项发表了独立意见，详见公司于同日刊登在巨潮资讯网上的《独 立董事关于相关事项的独立意见》。 表决结果：同意 7 票，反对 0 票，弃权 0 票。 三、审议通过了《关于聘任副总经理的议案》 同意聘任卢奕伟先生为公司副总经理，任期与第八届董事会任期一致。具体内容详 见公司于同日刊登在巨潮资讯网上的《关于聘任副总经 ...

内蒙古福瑞医疗科技股份有限公司 2023 年半年度非经营性资金占用及其他关联资金往来情况汇总表 | | | 占用方与上 | 上市公司核 | 2023 年期初 | 2023 年 1 月 1 日至 6 月 30 日 | 2023 年 1 月 1 | 2023 年 1 月 1 | 2023 年 6 月 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性 | 资金占用方 | 市公司的关 | 算的会计科 | 占用资金余 | 占用累计发生 | 日至 6 月 30 | 日至 6月30日 | 30 日占用 | 占用形成原 | 占用性质 | | 资金占用 | 名称 | | | | | 日占用资金 | 偿还累计发生 | | 因 | | | | | 联关系 | 目 | 额 | 金额（不含利 | | | 资金余额 | | | | | | | | | 息） | 的利息(如有) | 金额 | | | | | 控股股东、 | | | | | | | | | | 非经营性占用 | | 实 际 控 制 | | | | | | | | ...

内蒙古福瑞医疗科技股份有限公司 独立董事的独立意见 内蒙古福瑞医疗科技股份有限公司 独立董事关于相关事项的独立意见 根据中国证监会《上市公司独立董事管理办法》、深圳证券交易所《上市公司自律监 管指引第 2 号——创业板上市公司规范运作》等相关法律法规、规章制度的规定，作为内 蒙古福瑞医疗科技股份有限公司（以下简称"公司"）的独立董事，现对公司第八届董事 会第三次会议审议的相关事项发表如下独立意见： 一、独立董事关于公司 2023 年半年度控股股东及其他关联方资金占用情况的独立意见 经对公司 2023 年半年度控股股东及其他关联方资金占用情况进行认真核查：本报告期 内，公司不存在控股股东及其他关联方占用公司资金的情况，截止 2023 年 6 月 30 日，也 不存在以前年度发生并累计至 2023 年 6 月 30 日的违规关联方占用资金情况。 二、独立董事关于公司 2023 年半年度对外担保情况的独立意见 2、根据公司提供的副总经理的简历及其他有关材料，未发现其有《公司法》《深圳证 券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等规定的不得担任 经对公司 2023 年半年度对外担保情况进行认 ...

证券代码：300049 证券简称：福瑞股份 公告编号：2023-041 内蒙古福瑞医疗科技股份有限公司 关于 2023 年半年度计提、转回资产减值准备的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整、没有虚假 记载、误导性陈述或重大遗漏。 经公司测算，2023 年半年度计提各项资产减值准备共计 1,860,150.81 元，收回或转 回资产减值准备 14,995,879.30 元，其他变动 4,696,367.66 元。具体明细如下： 单位：元 | 类别 | 2022 年 12 月 31 | 本期计提 | 本期减少 | | 其他 | 2023 年 6 月 30 | | --- | --- | --- | --- | --- | --- | --- | | | 日余额 | | 收回或转回 | 核销 | | 日余额 | | 应收账款坏账 准备 | 29,329,540.97 | 1,606,560.96 | 9,375,581.85 | | 4,318,953.09 | 25,879,473.17 | | 其他应收款坏 账准备 | 6,391,079.02 | 253,589.85 | 5,620 ...

Group 1: Company Strategy and Development - The company plans to advance the Furui Health Technology Park project, aiming for completion in two years, integrating product R&D, a leading liver disease data center, and internet healthcare [1] - The company has a high management cost primarily due to high average salaries for overseas employees [1] - The company is focusing on the promotion of FibroScan Go, which is expected to increase revenue despite currently low income contribution [2] Group 2: Product and Market Insights - Theraclion's high-intensity focused ultrasound technology is primarily used for non-invasive treatments in varicose veins, thyroid tumors, and breast fibromas [2] - The global liver disease diagnostics market is projected to reach $29.27 billion by 2028, with FibroScan expected to capture a significant market share [4][6] - The NASH drug market is anticipated to grow rapidly, reaching $10.7 billion by 2025 and $32.2 billion by 2030, with compound annual growth rates of 41.8% and 24.6% respectively [6] Group 3: Financial Performance and Shareholder Information - As of May 31, 2023, the company had 13,249 shareholders [2] - The company's self-owned drug revenue increased by 9.33% year-on-year, with a gross margin increase of 1.60% [5] - The company is currently not planning to acquire the remaining 49% stake in Echosens [5] Group 4: Future Collaborations and Innovations - The company is considering further investments in Theraclion based on its development status [4] - There are no current plans for overseas promotion of the compound turtle shell soft liver tablets due to acceptance issues [3] - The company has no ongoing development of innovative drugs at this time [5]